Literature DB >> 20019609

Lung transplantation: is it still an experimental procedure?

Massimo Boffini1, Vito M Ranieri, Mauro Rinaldi.   

Abstract

PURPOSE OF REVIEW: The number of lung transplants performed worldwide is low and early and late results are worse in comparison with other solid organ transplants. The present review will focus on these two aspects analyzing the causes and describing the possible strategies to overcome these limitations. RECENT
FINDINGS: The use of grafts from marginal and from nonheart-beating donors may increase the number of lung transplantation (LTx) with good results. Implementation of donor protocol and optimization of donor management have been reported to be effective in increasing the pool of suitable grafts. Ex-vivo reconditioning technique may be also helpful to better evaluate and recondition usually rejected lungs. This may allow a significant increase in the number of lung transplants performed worldwide. Early and late results of LTx are mainly affected by primary graft dysfunction and the onset of obliterative bronchiolitis. Different strategies have been adopted to reduce the incidence of these two complications with controversial results.
SUMMARY: LTx maintains some features of experimental procedure especially in terms of number of performed procedures and early and late results. The various strategies to overcome the limited number of available grafts appear effective but not universally applied and accepted. The different treatments of PDG and obliterative bronchiolitis are still disappointing. To date, the onset of PDG and obliterative bronchiolitis after LTx still significantly impacts on outcomes. A better understanding of the underlying mechanisms in the pathogenesis of primary graft dysfunction and obliterative bronchiolitis may provide improved therapeutic strategies.

Entities:  

Mesh:

Year:  2010        PMID: 20019609     DOI: 10.1097/MCC.0b013e32833500a8

Source DB:  PubMed          Journal:  Curr Opin Crit Care        ISSN: 1070-5295            Impact factor:   3.687


  4 in total

Review 1.  Lung transplantation: a treatment option in end-stage lung disease.

Authors:  Marc Hartert; Omer Senbaklavacin; Bernhard Gohrbandt; Berthold M Fischer; Roland Buhl; Christian-Friedrich Vahld
Journal:  Dtsch Arztebl Int       Date:  2014-02-14       Impact factor: 5.594

2.  The role of autophagy in lung ischemia/reperfusion injury after lung transplantation in rats.

Authors:  Sheng Liu; Jun Zhang; Bentong Yu; Lei Huang; Bin Dai; Jichun Liu; Jian Tang
Journal:  Am J Transl Res       Date:  2016-08-15       Impact factor: 4.060

3.  The role of extracorporeal life support in the management with severe idiopathic pulmonary artery hypertension undergoing lung transplantation: are those patients referred too late?

Authors:  Anton Sabashnikov; Prashant N Mohite; Mohamed Zeriouh; Bartlomiej Zych; Diana García-Sáez; Johanna Maier; Alexander Weymann; Javid Fatullayev; Balakrishnan Mahesh; Aron-Frederik Popov; Ulrich Stock; Fabio De Robertis; Toufan Bahrami; Thorsten Wahlers; Martin Carby; André R Simon; Anna Reed
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

4.  Extracorporeal membrane oxygenation after lung transplantation: risk factors and outcomes analysis.

Authors:  Massimo Boffini; Erika Simonato; Davide Ricci; Fabrizio Scalini; Matteo Marro; Stefano Pidello; Matteo Attisani; Paolo Solidoro; Paolo Olivo Lausi; Vito Fanelli; Cristina Barbero; Luca Brazzi; Mauro Rinaldi
Journal:  Ann Cardiothorac Surg       Date:  2019-01
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.